Longboard Pharmaceuticals, Inc. is a US-based company in the commercial services industry with a medium risk assessment ESG score of 21.4. They are a clinical-stage biopharmaceutical company specializing in developing innovative medicines for neurological conditions. Longboard Pharmaceuticals focuses on creating centrally acting product candidates that target specific G protein-coupled receptors (GPCRs). One of their key developments is LP352, an oral 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist designed to potentially treat seizures related to various developmental and epileptic encephalopathies. Improve your portfolio with Longboard Pharmaceuticals, a leader in ESG-focused neuropharmaceuticals.